2cureX AB (publ) (STO:2CUREX)

Sweden flag Sweden · Delayed Price · Currency is SEK
1.978
-0.062 (-3.04%)
Apr 29, 2026, 12:35 PM CET
237.54%
Market Cap 51.21M
Revenue (ttm) 1.98M
Net Income (ttm) -26.35M
Shares Out 25.10M
EPS (ttm) -1.50
PE Ratio n/a
Forward PE n/a
Dividend 0.08 (3.67%)
Ex-Dividend Date Jun 27, 2025
Volume 57,655
Average Volume 149,111
Open 2.040
Previous Close 2.040
Day's Range 1.916 - 2.065
52-Week Range 0.514 - 5.520
Beta 2.79
RSI 72.39
Earnings Date May 21, 2026

About 2cureX AB

2cureX AB (publ) operates as a medical technology company in Europe. The company’s principal product is IndiTreat, an IVD test for the treatment of cancer by establishing 3D copies of the patient’s tumor and directly testing them against therapies. 2cureX AB (publ) was incorporated in 2006 and is based in Copenhagen, Denmark. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 14
Stock Exchange Nasdaq Stockholm
Ticker Symbol 2CUREX
Full Company Profile

Financial Performance

In 2023, 2cureX AB's revenue was 2.95 million, a decrease of -12.53% compared to the previous year's 3.37 million. Losses were -32.52 million, 9.23% more than in 2022.

Financial Statements

News

2cureX AB Transcript: Investor Update

Two new board members were elected to drive a transformation, including a shift to a direct-to-patient commercial model and the sale of the Danish-German subsidiary. The company is preparing for IVD-R certification and plans to scale operations, with proceeds from the asset sale to be distributed to shareholders.

1 year ago - Transcripts

2cureX AB Transcript: Investor Update

2 years ago - Transcripts

2cureX AB Transcript: Investor Update

3 years ago - Transcripts

2cureX AB Transcript: Investor Update

3 years ago - Transcripts